Soluble CTLA4 mutant molecules

Details Soluble CTLA4 mutant molecules Soluble CTLA4 mutant molecules

2006-08-22

2006-08-22

Gambel, Phillip (Department: 1644)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

C530S351000, C530S387100, C530S387300, C530S395000, C424S134100, C424S185100, C424S192100, C514S021800

Reexamination Certificate

active

07094874

ABSTRACT:
The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.

REFERENCES:
patent: 5434131 (1995-07-01), Linsley et al.
patent: 5521288 (1996-05-01), Brady et al.
patent: 5580756 (1996-12-01), Brady et al.
patent: 5637481 (1997-06-01), Ledbetter et al.
patent: 5770197 (1998-06-01), Linsley et al.
patent: 5773253 (1998-06-01), Linsley et al.
patent: 5844095 (1998-12-01), Linsley et al.
patent: 5851795 (1998-12-01), Linsley et al.
patent: 5883223 (1999-03-01), Gray
patent: 5885579 (1999-03-01), Linsley et al.
patent: 5885796 (1999-03-01), Linsley et al.
patent: 5916560 (1999-06-01), Larsen et al.
patent: 5958403 (1999-09-01), Strom et al.
patent: 5968510 (1999-10-01), Linsley et al.
patent: 5977318 (1999-11-01), Linsley et al.
patent: 5993800 (1999-11-01), Linsley et al.
patent: 6090914 (2000-07-01), Linsley et al.
patent: 6132992 (2000-10-01), Ledbetter et al.
patent: 6352694 (2002-03-01), June et al.
patent: 6444792 (2002-09-01), Gray et al.
patent: 6534055 (2003-03-01), June et al.
patent: 6641809 (2003-11-01), Brady et al.
patent: 6685941 (2004-02-01), Thompson et al.
patent: 6719972 (2004-04-01), Gribben et al.
patent: 6750334 (2004-06-01), Gray et al.
patent: 6830937 (2004-12-01), Brady et al.
patent: 6887471 (2005-05-01), Linsley et al.
patent: 2001/0053361 (2001-12-01), Thompson et al.
patent: 2002/0031510 (2002-03-01), Larsen et al.
patent: 2002/0039577 (2002-04-01), Todderud et al.
patent: 2002/0115214 (2002-08-01), June et al.
patent: 2003/0007968 (2003-01-01), Adams et al.
patent: 2003/0022836 (2003-01-01), Larsen et al.
patent: 2003/0083246 (2003-05-01), Cohen et al.
patent: 2003/0219863 (2003-11-01), Peach et al.
patent: 2004/0014171 (2004-01-01), Peach et al.
patent: 2004/0022787 (2004-02-01), Cohen et al.
patent: 2005/0019859 (2005-01-01), Schilling et al.
patent: 2005/0084933 (2005-04-01), Schilling et al.
patent: 2005/0123539 (2005-06-01), Rusnak
patent: 0 613 944 (1994-09-01), None
patent: 0 682 039 (1995-11-01), None
patent: 757099 (1997-05-01), None
patent: WO 90/05541 (1990-05-01), None
patent: WO 93/00431 (1993-01-01), None
patent: WO 93/19767 (1993-10-01), None
patent: WO 94/28912 (1994-12-01), None
patent: WO 95/01994 (1995-01-01), None
patent: WO 95/33770 (1995-12-01), None
patent: WO 95/34320 (1995-12-01), None
patent: WO 97/34633 (1997-03-01), None
patent: WO 97/28267 (1997-08-01), None
patent: WO 97/37687 (1997-10-01), None
patent: WO 97/47732 (1997-12-01), None
patent: WO 98/31820 (1998-07-01), None
patent: WO 98/33513 (1998-08-01), None
patent: WO 98/56417 (1998-12-01), None
patent: WO 99/29883 (1999-06-01), None
patent: WO 99/47558 (1999-09-01), None
patent: WO 99/49734 (1999-10-01), None
patent: WO 99/51275 (1999-10-01), None
patent: WO 99/57266 (1999-11-01), None
patent: WO 01/92337 (2001-12-01), None
patent: WO 02/02638 (2002-01-01), None
patent: WO 04/058800 (2004-07-01), None
patent: WO 04/058944 (2004-07-01), None
patent: WO 05/016266 (2005-02-01), None
Turka et al. (1992), Proc. Natl. Acad. Sci USA 89:11102-11105 (Exhibit 24).
Lenschow et al. (1992) Science 257: 789-792 (Exhibit 25).
Linsley et al. (1992) Science 257: 792-795 (Exhibit 26).
Linsley et al. (1992) J. Exp. Med. 176:1595-1604 (Exhibit 27).
Tan et al. (1993) J. Exp. Med. 177:165-173 (Exhibit 28).
Linsley et al. (1994) Immunity 1:793-801 (Exhibit 29).
Peach et al. (1994) J. Exp. Med. 180:2049-2058 (Exhibit 30).
Steurer et al. (1995) J. Immunol. 155:1165-1174. (Exhibit 31).
Fargeas et al. (1995) J. Exp. Med. 182:667-675. (Exhibit 32).
Peach et al. (1995) J. Biol. Chem. 270(36): 21181-21187. (Exhibit 33).
Alegre et al. (1995) Dig. Dis. Sci. 40(1):58-64. (Exhibit 34).
Guo et al. (1995) J. Exp. Med. 181:1345-1355. (Exhibit 35).
Rattis et al. (1996) Eur. J. Immunol. 26:449-453. (Exhibit 36).
Murakami et al. (1996) Proc. Nat. Acad. Sci. USA 93:7838-7842. (Exhibit 37).
Morton et al. (1996) J. Immol.Feb. 1; 156:1047-1054. (Exhibit 38).
Parsons et al (1996) Immunogenetics 43:388-391. (Exhibit 39).
Oaks et al (1996 Immunogenetics 43:172-174. (Exhibit 40).
Peach et al. (1995) Methods 8:116-123 (Exhibit 41).
Harris et al. (1997) J. Exp. Med. 185:177-182 (Exhibit 42).
Greene et al. (1996) J. Bio. Chem. 271:26762-26771 (Exhibit 43).
van der Merwe et al. (1997) J. Exper. Med. 185:393-403. (Exhibit 44).
Gailon et al. (1997) J. Immunol. 159:4212-4216. (Exhibit 45).
Höllsberg et al. (1997) J Immunol. 159:4799-4805. (Exhibit 46).
Bajorath et al. (1997) J Mol Graphics and Modeling 15:135-139. (Exhibit 47).
Greenwald et al. (1997) J. Immunol. 158:4088-4096. (Exhibit 48).
Metzler et al. (1997) Nat Struc Bio 4:527-531. (Exhibit 49).
Nuttall et al. (1999) Proteins: Structure, Functions, and Genetics 36:217-227. (Exhibit 51).
Pearson et al. (2000) Transplantation 69:S-123. (Exhibit 52) (Abstract #44).
Reynolds et al. (2000) J Clinical Investigation 105:643-651. (Exhibit 53).
Cinek et al. (2000) J Immunol. 164:5-8. (Exhibit 54).
Masteller et al. (2000) J Immunol. 164:5319-5327. (Exhibit 55).
Hufton et al. (2000) FEBS Letters 475:225-231. (Exhibit 56).
Larsen, Christian P. (2000) LEA29Y 20 Pages of Slides (Exhibit 57).
Linsley, et al., 1991,J.Exp.Med.CTLA-4 Is a Second Receptor for the B Cell Activation Antigen B7 174:561-569. (Exhibit 65).
Gimmi, et al., 1993,Proc.Natl.Acad.Sci. USA“Human T-Cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation” 90:6586-6590. (Exhibit 66).
Azuma et al., 1993Nature“B70 antigen is a second ligand for CTLA-4 and CD28” 366:76-79. (Exhibit 67).
Ronchese et al., 1994J.Exp.Med“Mice Transgenic for a Soluble Form of Murine CTLA-4Show Enhanced Expansion of Antigen-Specific CD4 T Cells and Defective Antibody production In Vivo” 179:809-817. (Exhibit 68).
Griggs et al., 1996J.Exp.Med“The Relative Contribution of the CD28 and gp39 Costimulatory pathways in the Clonal Expansion and Pathgenic Acquisition of Self-reactive T Cells” 183:801-810. (Exhibit 69).
Linsley et al.,J.Exp.Med“CTLA-4 Is a Second Receptor for the B Cell Activation Antigen B7” 174:561-569. (Exhibit 70).
Verwilghen et al., 1994J-Immunol.Expressionof Functional B& and CTLA4 on Rheumatoid Synovial T Cells 153:1378-1385. (Exhibit 71).
Blazar et al., 1994Blood“In Vivo Blockade of CD28/CTLA4: Interaction With CTLA4-Ig Reduces Lethal Murine Graft-Versus-Host Disease Across the Major Histocompatibility Complex Barrier in Mice” 83:3815-3825. (Exhibit 72).
Finck et al.,Science“Treatment of Murine lupus with CTLA4Ig” 265:1225-1227. (Exhibit 73).
Perrin et al., 1995J-Immunol“Role of B7:CD28/CTLA4 in the Induction of Chronic Relapsing Experimental Allergic Encephalomyelitis” 154:1481-1490. (Exhibit 74).
Pearson et al., 1994Transplantation“Tranplantation Tolerance Induced By CTLA4-Ig” 57:1701-1706. (Exhibit 75).
Baliga et al., 1994Transplantation“CTLA4Ig Prolongs Allograft Survival While Suppressing Cell-Mediated Immunity” 58:1082-1090. (Exhibit 76).
Tepper et al. 1994Transplantation Proceedings“Tolerance Induction by soluble CTLA4 in a Mouse Skin Transplant Model” 26:3151-3154. (Exhibit 77).
Perico et al., 1995Kidney International“Toward novel antirejection strategies: In vivo immunosuppressive properties of CTLA4Ig” 47:241-246. (Exhibit 78).
Finck et al., 1994Arthritis and Rheumatism“Effects of CTLA4Ig in murine lupus” 37:S222. (Exhibit 79) Abstract #375.
Nishikawa et al., 1994Eur J. Immunol.“Effect of CTLA-4 chimeric protein on rat autoimmune anti-glomerular basement membrane glomerulonephritis” 24:1249-1254. (Exhibit 80).
Wallace et al., 1994Transplantat

Affiliated with

Also associated with

Rating

Soluble CTLA4 mutant molecules does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Soluble CTLA4 mutant molecules, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Soluble CTLA4 mutant molecules will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3683489